InFlectis BioScience is a France-based clinical stage company committed to the development of innovative therapeutics harnessing the Integrated Stress Response for the treatment of a broad range of diseases.

The Company is currently focusing on the development of a treatment for Charcot-Marie-Tooth disease (CMT).

Anticipated Milestones

  • Completion of clinical Phase 1 study in healthy volunteers by Q4 2019;
  • Start of clinical Phase 2 studies in Charcot-Marie-Tooth disease 1A and 1B by S2 2020.